Dr Lal Pathlabs Ltd (LALPATHLAB) is currently trading at 1,910.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Dr. Lal PathLabs is a leading diagnostic healthcare service provider in India, offering over 5000 tests through an extensive national network of labs and service centers. Despite industry challenges, the company achieved a 10.6% YoY increase in revenue for Q3 FY26, underscoring its ability to sustain growth through strategic moves like network expansion and introduction of new tests. The launch of Sovaaka, a personalized preventive healthcare platform, has been pivotal, marking a shift towards preventive and predictive healthcare services, leveraging advanced diagnostics and AI technology. Significant strides in increasing high-end diagnostic portfolios signal the company's focus on capturing a larger share of the preventive and specialty diagnostics markets, particularly through specialized centers and new test introductions. Dr. Lal PathLabs' financial resilience is evident from its robust EBITDA margins and strategic reinvestment in growth areas like high-end radiology, demonstrating both operational efficiency and strategic foresight.

Over the past 52 weeks, Dr Lal Pathlabs Ltd has traded between a low of ₹1,272.00 and a high of ₹2,035.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Dr Lal Pathlabs Ltd has a market capitalization of approximately 31,821.62. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Dr Lal Pathlabs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 58.25 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 31,821.62 Cr, Dr Lal Pathlabs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Dr Lal Pathlabs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Dr Lal Pathlabs Ltd is 58.25. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The earnings conference call was held on July 24, 2026, and the company later released the transcript in line with SEBI listing disclosure requirements.

Dr Lal PathLabs’ upcoming earnings date is July 24, 2026, when the board will consider and approve unaudited results for the quarter ended June 30, 2026.

The company has scheduled a Board meeting on July 24, 2026 to consider and approve the unaudited results for Q1 FY26-27.

The stock rose 11% to ₹1,803.60 after the company reported Q4 FY26 revenue of ₹703 crore, up 16.6% year-on-year, driven mainly by higher sample volumes.